- Date 1 May 2018
Ahren Innovation Capital has led the successful $30 million Series C funding round for Cambridge Epigenetix (“CEGX”) with strong participation from existing investors. CEGX is a pioneer in the development and application of epigenetic technologies and aims to change the way medicine is practiced by reducing several routine and important diagnostic screening tests to a simple blood draw using the power of the 5-hydroxymethylcytosine (5hmC) epigenetic modification.
CEGX’s proprietary discovery platform enables the affordable and accurate identification of disease- specific hydroxymethylated (5hmC) DNA from blood and tissue samples — enhancing human health through more accurate and earlier diagnosis of cancer, improved patient stratification and the development of liquid biopsy-based tests.
CEGX, spun out of the University of Cambridge in 2012 and co-founded by Sir Shankar Balasubramanian (co-inventor of Solexa sequencing) and Dr Bobby Yerramilli-Rao, is at the forefront of the revolutionary field of epigenetics and has attracted investment from world leading investors including Ahren Innovation Capital, Sequoia, GV, New Sciences Ventures and Syncona.
Jason Mellad, PhD, CEO at CEGX, said; “This funding will give us the potential to transform patient care. As a person’s epigenetic code changes over time, testing could become routine and regular. Ahren Innovation Capital is a great partner for CEGX, sharing our vision and values, and I know they will contribute to our long-term success.”
Alice Newcombe-Ellis, Founder & Managing Partner, Ahren Innovation Capital added; “CEGX is founded on deep scientific research. They are at the cutting edge of this science and bring a seasoned team with a fantastic track record. It is an exciting moment for the company, in a large and vital market. This is just the beginning and we share the vision of the Founders and current management of using deep science and deep data to keep pushing scientific boundaries.”